Statement: Gastrointestinal haemorrhage was more common in patients from cohort 2 of the secondary trial. than cohort 1 of the primary trial .
Primary_evidence: Adverse Events 1:   Total: 13/83 (15.66%)   Cardiac failure congestive 1/83 (1.20%)   Hypothyroidism 1/83 (1.20%)   Nausea 2/83 (2.41%)   Vomiting 2/83 (2.41%)   Diarrhea 1/83 (1.20%)   Gastrointestinal Haemorrhage 1/83 (1.20%)   Asthenia 1/83 (1.20%)   Hyperbilirubinaemia 1/83 (1.20%)   Anal abscess 1/83 (1.20%)   Dehydration 3/83 (3.61%)   Decreased appetite 1/83 (1.20%)
Secondary_evidence: Adverse Events 1:   Total: 7/26 (26.92%)   Febrile neutropenia 1/26 (3.85%)   Neutropenia 0/26 (0.00%)   Thrombocytopenia 0/26 (0.00%)   Cardiac failure congestive 0/26 (0.00%)   Extrasystoles 0/26 (0.00%)   Nausea 1/26 (3.85%)   Abdominal pain 0/26 (0.00%)   Constipation 0/26 (0.00%)   Gastrointestinal haemorrhage 0/26 (0.00%)   Death - unknown cause 1/26 (3.85%)   Thrombosis in device 0/26 (0.00%) Adverse Events 2:   Total: 5/10 (50.00%)   Febrile neutropenia 0/10 (0.00%)   Neutropenia 0/10 (0.00%)   Thrombocytopenia 1/10 (10.00%)   Cardiac failure congestive 0/10 (0.00%)   Extrasystoles 0/10 (0.00%)   Nausea 0/10 (0.00%)   Abdominal pain 0/10 (0.00%)   Constipation 0/10 (0.00%)   Gastrointestinal haemorrhage 0/10 (0.00%)   Death - unknown cause 0/10 (0.00%)   Thrombosis in device 0/10 (0.00%)